Roy D. Baynes, Director at Travere Therapeutics (NASDAQ:TVTX), reported the exercise and immediate sale of 4,500 common shares for a transaction value of approximately $210,000, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($46.65); post-transaction value based on May 5, 2026 market close ($44.80).
* 1-year performance calculated using May 8th, 2026 as the reference date.
This rare disease therapeutics specialist reported a notable insider sale amid a year of strong share price gains and pipeline progress.
Roy D. Baynes, Director at Travere Therapeutics (TVTX 0.14%), reported the exercise and immediate sale of 4,500 common shares for a transaction value of approximately $210,000, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares traded (direct) | 4,500 |
| Transaction value | $210,000 |
| Post-transaction shares (direct) | 37,500 |
| Post-transaction value (direct ownership) | ~$1.68 million |
Transaction value based on SEC Form 4 weighted average purchase price ($46.65); post-transaction value based on May 5, 2026 market close ($44.80).
Key questions
- How does this transaction affect Roy D. Baynes’s ownership in Travere Therapeutics?
Following this option exercise and sale, Baynes’s direct holdings decreased by 4,500 shares, amounting to a 10.71% reduction in his direct position, with a remaining balance of 37,500 shares. - What is the structure of this transaction from a derivative perspective?
This event involved the exercise of fully vested options for 4,500 shares, which were immediately sold for liquidity. - Was this transaction part of a pre-arranged selling plan?
the sale was made under a 10b5-1 plan adopted November 17, 2025 (Form 4, footnote 1) - How does the trade align with Baynes’s recent selling cadence and capacity?
Recent transactions show a pattern of option-related sales as direct holdings have declined, and the size of this trade reflects a lower available share capacity.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 2026-05-08) | $42.59 |
| Market capitalization | $3.96 billion |
| Revenue (TTM) | $536.20 million |
| 1-year price change | 108.4% |
* 1-year performance calculated using May 8th, 2026 as the reference date.
Company snapshot
- Travere Therapeutics generates revenue primarily from rare disease therapies, including marketed products such as Chenodal, Cholbam, and Thiola/Thiola EC, as well as late-stage pipeline candidates like Sparsentan and TVT-058.
- The company operates a biopharmaceutical business model focused on the development, approval, and commercialization of specialty drugs for underserved rare disease indications.
Travere Therapeutics is a biotechnology company specializing in the development and commercialization of therapies for rare diseases, with a focus on metabolic and renal indications. The company leverages a targeted portfolio of approved products and late-stage pipeline assets to address unmet medical needs in niche patient populations. Travere’s strategy centers on advancing innovative treatments through clinical development and strategic partnerships, positioning the firm as a competitive player in the rare disease therapeutics sector.
What this transaction means for investors
This sale was executed under a 10b5-1 plan Baynes adopted in November 2025 — months before the transaction date. The decision to sell had nothing to do with anything happening at Travere in May 2026, and reading it as a directional signal would be a mistake. The mechanics are straightforward: he exercised options with an $18.27 strike, sold at $46.65, and netted roughly $127,700 after exercise costs. He still holds 37,500 shares directly, worth about $1.6 million at current prices. What’s worth noting is where the stock sat when the plan executed. TVTX has a 52-week range of $13.88–$48.61, and this sale cleared near the top of it. That’s a decent result for a pre-scheduled transaction, but Baynes left most of his position on the table — which is the more relevant data point for anyone trying to gauge insider conviction.
